Annexin Pharmaceuticals AB Cash Flow Conversion Efficiency
Annexin Pharmaceuticals AB cash flow conversion efficiency. Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.716x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.33 Million ≈ $-1.11 Million USD) by net assets (Skr14.42 Million ≈ $1.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Annexin Pharmaceuticals AB (2015–2025)
Cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Annexin Pharmaceuticals AB stock price for real-time trading data and today's change.
Annexin Pharmaceuticals AB Cash Flow Conversion Ratio Explained
Annexin Pharmaceuticals AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency. Also see market value of Annexin Pharmaceuticals AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Whitebark Energy Ltd
AU:WBE
|
0.308x |
|
Eversafe Rubber Bhd
KLSE:0190
|
0.069x |
|
ArcWest Exploration Inc
V:AWX
|
-0.016x |
|
Core AI Holdings
NASDAQ:CHAI
|
2.203x |
|
Codrus Minerals Ltd
AU:CDR
|
-3.152x |
|
Marvel Biosciences Corp
V:MRVL
|
0.049x |
|
Destiny Media Technologies Inc
V:DSY
|
0.158x |
|
Opyl Ltd
AU:OPL
|
1.994x |
Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. Review ANNX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr24.93 Million ≈ $2.68 Million |
Skr-36.92 Million ≈ $-3.97 Million |
-1.481x | +59.57% |
| 2024-12-31 | Skr13.71 Million ≈ $1.48 Million |
Skr-50.23 Million ≈ $-5.41 Million |
-3.663x | -58.77% |
| 2023-12-31 | Skr18.81 Million ≈ $2.02 Million |
Skr-43.40 Million ≈ $-4.67 Million |
-2.307x | -68.98% |
| 2022-12-31 | Skr30.15 Million ≈ $3.24 Million |
Skr-41.16 Million ≈ $-4.43 Million |
-1.365x | -41.68% |
| 2021-12-31 | Skr46.73 Million ≈ $5.03 Million |
Skr-45.02 Million ≈ $-4.85 Million |
-0.964x | +49.27% |
| 2020-12-31 | Skr20.64 Million ≈ $2.22 Million |
Skr-39.20 Million ≈ $-4.22 Million |
-1.899x | +15.17% |
| 2019-12-31 | Skr11.49 Million ≈ $1.24 Million |
Skr-25.73 Million ≈ $-2.77 Million |
-2.239x | -213.04% |
| 2018-12-31 | Skr39.85 Million ≈ $4.29 Million |
Skr-28.50 Million ≈ $-3.07 Million |
-0.715x | +55.27% |
| 2017-12-31 | Skr24.44 Million ≈ $2.63 Million |
Skr-39.08 Million ≈ $-4.21 Million |
-1.599x | -150.32% |
| 2016-12-31 | Skr15.57 Million ≈ $1.68 Million |
Skr-9.95 Million ≈ $-1.07 Million |
-0.639x | -101.75% |
| 2015-12-31 | Skr-137.00K ≈ $-14.74K |
Skr-5.01 Million ≈ $-539.37K |
36.584x | -- |
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmo… Read more